Callan Family Office LLC Buys New Position in Bristol Myers Squibb Company $BMY

Key Points

• Callan Family Office purchased 62,042 Bristol Myers Squibb shares worth approximately $3.6 million, while institutional investors collectively own 76.41% of the company.
• Analyst sentiment is broadly positive: Bristol Myers Squibb has a “Moderate Buy” consensus rating and an average price target of $66.06, with several firms recently issuing bullish ratings or raising targets.
• The company exceeded quarterly earnings and revenue expectations, reported 5.7% year-over-year revenue growth, and maintains a quarterly dividend of $0.63 per share, representing a 3.8% yield.

Callan Family Office LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 62,042 shares of the biopharmaceutical company's stock, valued at approximately $3,575,000.

A number of other large investors have also modified their holdings of the business. Expressive Wealth LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $521,000. Fund Advisors of America Inc FL acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at approximately $276,000. Shelter Mutual Insurance Co purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $3,100,000. Causey Wealth LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $418,000. Finally, Keebeck Wealth Management acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth $955,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

BMY has been the topic of several research reports. JPMorgan Chase & Co. upped their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research report on Friday, July 31st. Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday. Raymond James Financial assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating on the stock. Piper Sandler assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued an "overweight" rating for the company. Finally, Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the stock an "equal weight" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb currently has an average rating of "Moderate Buy" and a consensus target price of $66.06.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Bristol Myers Squibb Trading Up 2.4%

NYSE BMY opened at $67.06 on Friday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The company has a market capitalization of $136.98 billion, a PE ratio of 14.77, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a fifty day moving average of $60.55 and a 200 day moving average of $59.37.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm's revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source